Robenacoxib (Onsior)

Robenacoxib, marketed under the brand name Onsior, represents a significant advancement in feline pain management as one of the few nonsteroidal anti-inflammatory drugs specifically approved for use in cats. This medication belongs to the coxib class of NSAIDs, which selectively inhibits the cyclooxygenase-2 (COX-2) enzyme while largely sparing the COX-1 enzyme. This selectivity is particularly important in cats, a species historically known for their sensitivity to traditional NSAIDs and their limited ability to metabolize many drugs in this class. Robenacoxib has become a cornerstone of multimodal pain management in feline medicine, offering veterinarians a reliable option for controlling pain and inflammation in their feline patients.

The mechanism of action of robenacoxib centers on its highly selective inhibition of the COX-2 enzyme, which is primarily responsible for producing prostaglandins involved in pain, inflammation, and fever responses. By targeting COX-2 while minimizing effects on COX-1, robenacoxib reduces the production of inflammatory mediators at sites of tissue damage without significantly disrupting the protective prostaglandins that maintain gastrointestinal mucosal integrity, support renal blood flow, and promote normal platelet function. This selective action results in effective anti-inflammatory and analgesic effects with an improved safety margin compared to non-selective NSAIDs. The drug reaches peak plasma concentrations rapidly and preferentially accumulates at sites of inflammation, providing targeted pain relief where it is needed most.

Robenacoxib is available in two primary formulations for feline use: oral tablets and an injectable solution. The oral tablets are flavored to improve palatability and are typically administered once daily for short-term use following surgical procedures or for the management of acute pain conditions. The injectable formulation provides rapid onset of action and is commonly used perioperatively, with administration occurring before surgery to provide preemptive analgesia. Both formulations offer flexibility in clinical settings, allowing veterinarians to choose the most appropriate route based on the patient's condition, the clinical scenario, and owner compliance considerations.

The safety profile of robenacoxib in cats has been extensively studied, with clinical trials demonstrating good tolerability when used according to label directions. However, as with all NSAIDs, appropriate patient selection, accurate dosing based on current body weight, and adherence to recommended treatment durations are essential for minimizing risks. Veterinary supervision is crucial when using robenacoxib, as cats require careful monitoring for any signs of adverse effects. The medication should only be used under the guidance of a licensed veterinarian who can assess whether robenacoxib is appropriate for an individual cat based on their complete health history, current condition, and concurrent medications.

The primary FDA-approved indication for robenacoxib in cats is the control of postoperative pain and inflammation associated with orthopedic surgery, ovariohysterectomy, and castration. In these surgical contexts, robenacoxib provides effective analgesia during the critical recovery period when cats are most vulnerable to pain and discomfort. The ability to administer the injectable formulation preoperatively allows for preemptive analgesia, which research has shown to be more effective at controlling postoperative pain than treatment initiated after surgical trauma has occurred. This makes robenacoxib an integral component of modern surgical pain management protocols in feline practice.

Beyond its primary surgical applications, robenacoxib demonstrates significant efficacy in managing acute musculoskeletal pain and inflammation in cats. Soft tissue injuries, sprains, strains, and acute flare-ups of underlying orthopedic conditions respond well to short-term robenacoxib therapy. The drug's rapid onset of action and preferential distribution to inflamed tissues make it particularly well-suited for these acute pain scenarios. Cats suffering from trauma-related pain, whether from falls, motor vehicle incidents, or other injuries, may benefit from robenacoxib as part of a comprehensive pain management approach that addresses both the inflammatory and nociceptive components of their discomfort.

While not specifically labeled for chronic use in the United States, robenacoxib has gained approval in some international markets for longer-term management of pain and inflammation associated with chronic musculoskeletal disorders, including feline osteoarthritis. Osteoarthritis is increasingly recognized as a common condition in cats, particularly in older populations, where radiographic evidence of degenerative joint disease may be present in a majority of geriatric patients. In jurisdictions where extended use is approved, robenacoxib offers a valuable option for improving mobility and quality of life in cats suffering from chronic joint pain, though careful monitoring and regular veterinary reassessment remain essential.

Veterinarians may also consider robenacoxib for pain management in cats with other inflammatory conditions where NSAID therapy is deemed appropriate. This includes certain dental procedures, minor surgical interventions, and acute inflammatory episodes of various etiologies. The decision to use robenacoxib in these contexts requires careful clinical judgment, weighing the benefits of pain control against potential risks based on the individual patient's health status. The drug's favorable safety profile compared to other NSAIDs makes it a preferred choice when anti-inflammatory and analgesic therapy is indicated in feline patients.

The selection of robenacoxib over alternative pain management options often depends on several factors specific to the individual cat and clinical situation. For cats requiring potent anti-inflammatory effects alongside analgesia, robenacoxib offers advantages over pure analgesics that lack anti-inflammatory properties. Its availability in both injectable and oral formulations provides flexibility throughout the treatment course, allowing for hospital-based injectable administration transitioning to at-home oral therapy. The once-daily dosing schedule for the oral formulation also enhances owner compliance compared to medications requiring multiple daily administrations, an important consideration in feline patients where medication administration can be challenging.

The dosing of robenacoxib in cats must be determined by a licensed veterinarian based on the individual patient's weight, health status, and the specific condition being treated. Accurate body weight measurement is essential, as dosing is calculated on a milligram per kilogram basis, and even small errors in weight estimation can result in under- or over-dosing in feline patients. Veterinarians will assess each cat individually to determine the appropriate dose, formulation, and duration of therapy, taking into account factors such as the severity of pain or inflammation, the cat's overall health, kidney and liver function, and any concurrent medications or medical conditions.

For the injectable formulation, robenacoxib is typically administered as a single subcutaneous injection at a dose of approximately 2 mg/kg body weight. This injection is commonly given preoperatively to provide preemptive analgesia, with administration occurring approximately 30 minutes before the surgical procedure. The injectable form provides rapid onset of action, with therapeutic concentrations achieved quickly following administration. In some cases, a second injection may be given 24 hours after surgery if continued injectable therapy is deemed necessary, though many protocols transition to oral medication for continued pain management at home.

The oral tablet formulation of robenacoxib is administered once daily at a dose of approximately 1-2 mg/kg body weight, depending on the specific product labeling in the region of use. Tablets should be given without food for optimal absorption, as feeding can reduce the rate and extent of drug absorption. However, if gastrointestinal upset occurs, veterinarians may recommend administration with a small amount of food to improve tolerability. The tablets are designed to be palatable for cats, though some individuals may require the tablet to be hidden in a treat or administered using a pill popper device. Treatment duration for acute postoperative pain is typically limited to a maximum of three consecutive days as per FDA labeling in the United States.

The timing of robenacoxib administration is an important consideration for optimal pain control. For surgical patients, the preoperative injectable dose should be given according to the veterinarian's protocol to ensure adequate drug levels are present at the time of surgical incision. When transitioning from injectable to oral therapy, the first oral dose is typically given approximately 24 hours after the injection. For oral therapy initiated without prior injection, the first dose should be given as soon as pain management is indicated, with subsequent doses administered at approximately 24-hour intervals.

If a dose of robenacoxib is missed, cat owners should contact their veterinarian for guidance rather than attempting to make dosing decisions independently. Generally, if a missed dose is recognized within a few hours of the scheduled time, it may be appropriate to give the dose at that time. However, if a significant portion of the dosing interval has passed, it is typically recommended to skip the missed dose and resume the regular schedule with the next dose. Owners should never give a double dose to compensate for a missed dose, as this significantly increases the risk of adverse effects, particularly gastrointestinal and renal complications.

Completing the full course of robenacoxib therapy as prescribed by the veterinarian is important for optimal pain management outcomes. While cat owners may observe improvement in their pet's comfort before the prescribed course is complete, discontinuing medication prematurely may result in inadequate pain control during the healing process. Conversely, extending treatment beyond the prescribed duration without veterinary authorization increases the risk of adverse effects and should be avoided. If pain persists beyond the initial treatment course, owners should consult their veterinarian for reassessment rather than continuing or restarting medication independently.

Robenacoxib demonstrates a favorable safety profile in cats when used according to label directions, with the majority of feline patients tolerating the medication well during short-term therapy. The COX-2 selective nature of robenacoxib contributes to its improved gastrointestinal safety compared to non-selective NSAIDs, though adverse effects can still occur and cat owners should be educated about what to watch for during treatment. Monitoring cats carefully during any NSAID therapy is essential, as early recognition of adverse effects allows for prompt intervention and typically results in better outcomes.

The most commonly observed side effects of robenacoxib in cats involve the gastrointestinal system. These may include decreased appetite, vomiting, diarrhea, and soft stools. In clinical trials, these gastrointestinal effects were generally mild and self-limiting, often resolving without specific treatment. However, persistent vomiting, bloody vomit, dark tarry stools indicating gastrointestinal bleeding, or complete refusal to eat warrant immediate veterinary attention. Cats experiencing these signs should have their robenacoxib therapy discontinued pending veterinary evaluation, as continued administration could exacerbate gastrointestinal injury.

Moderate side effects that may occur with robenacoxib use include changes in kidney or liver function parameters. While the COX-2 selectivity of robenacoxib provides some degree of renal sparing compared to non-selective NSAIDs, prostaglandins still play important roles in maintaining renal blood flow, particularly in cats with compromised cardiovascular or renal status. Signs of kidney problems may include increased thirst and urination, decreased urination, lethargy, or loss of appetite. Liver-related adverse effects, though less common, may manifest as jaundice (yellowing of the gums, skin, or whites of the eyes), persistent vomiting, or severe lethargy. Any of these signs should prompt immediate discontinuation of the medication and veterinary consultation.

Serious adverse reactions to robenacoxib, while rare, can occur and require emergency veterinary care. Allergic reactions may manifest as facial swelling, hives, difficulty breathing, or sudden collapse. Severe gastrointestinal complications including perforation or significant hemorrhage represent medical emergencies. Signs of acute kidney injury such as sudden cessation of urination, severe lethargy, or vomiting require immediate attention. Additionally, any significant behavioral changes, neurological signs such as seizures or incoordination, or unexplained bleeding should be treated as urgent situations requiring prompt veterinary evaluation.

Rare and idiosyncratic reactions to robenacoxib can occur unpredictably in individual cats. These may include unusual skin reactions, blood cell abnormalities, or unexpected organ effects. Long-term use concerns, where applicable in regions where extended therapy is approved, include the potential for cumulative effects on kidney function and the possibility of gastrointestinal ulceration developing over time. Cats should be monitored with periodic blood work and clinical examinations during any extended NSAID therapy. Any new or worsening signs during treatment should prompt veterinary consultation, and owners should err on the side of caution by seeking professional advice whenever they are concerned about their cat's response to the medication.

Robenacoxib is contraindicated in cats with known hypersensitivity or allergic reactions to the drug or to other NSAIDs. Cats that have previously experienced adverse reactions to any NSAID, including aspirin, meloxicam, or other coxib-class drugs, should not receive robenacoxib due to the potential for cross-reactivity within this drug class. Previous reactions may have included gastrointestinal upset, allergic symptoms, kidney problems, or other adverse effects. It is essential that cat owners inform their veterinarian of any previous medication reactions their cat has experienced, as this history directly influences the safety of prescribing robenacoxib or any alternative NSAID.

Pre-existing kidney disease represents a significant contraindication for robenacoxib use in cats. Chronic kidney disease is extremely common in the feline population, particularly in middle-aged and older cats, and NSAIDs can exacerbate renal dysfunction through their effects on prostaglandin-mediated renal blood flow. Cats with known kidney disease, elevated kidney values on blood work, or clinical signs of renal compromise should not receive robenacoxib unless the potential benefits clearly outweigh the risks and no safer alternatives exist. Similarly, cats with liver disease or abnormal liver function tests may be unable to properly metabolize robenacoxib, increasing the risk of drug accumulation and toxicity. Dehydrated or hypovolemic cats are also at increased risk for NSAID-induced kidney injury and should have their fluid status corrected before NSAID therapy is considered.

Robenacoxib should not be used in pregnant or nursing cats due to insufficient safety data in these populations and the known effects of prostaglandin inhibition on reproductive function and fetal development. NSAIDs can interfere with ovulation, implantation, and normal pregnancy maintenance, and may cause premature closure of the ductus arteriosus in developing fetuses. Nursing queens should avoid robenacoxib as the drug may be excreted in milk and affect nursing kittens. Cats intended for breeding should not receive robenacoxib during breeding periods. Additionally, the safety of robenacoxib in very young kittens has not been established, and use in cats younger than four months of age is generally not recommended.

Other medical conditions that contraindicate robenacoxib use include bleeding disorders or concurrent anticoagulant therapy, as NSAIDs affect platelet function and can increase bleeding risk. Cats with gastrointestinal ulceration or a history of NSAID-induced gastrointestinal bleeding should not receive robenacoxib. Cardiac conditions, particularly congestive heart failure, represent relative contraindications due to the fluid-retaining effects of NSAIDs and their potential to worsen cardiac function. Cats with blood pressure abnormalities should be carefully evaluated before NSAID therapy. Complete disclosure of a cat's medical history to the veterinarian is essential, as many conditions may influence the safety of robenacoxib therapy, and the veterinarian needs complete information to make appropriate prescribing decisions.

Informing the veterinarian of all medications, supplements, and over-the-counter products a cat is receiving is essential before starting robenacoxib therapy. Drug interactions can significantly affect the safety and efficacy of treatment, potentially leading to increased toxicity, reduced effectiveness, or unexpected adverse effects. Even products that seem harmless, including vitamins, supplements, and herbal remedies, can interact with robenacoxib and should be disclosed. The veterinarian can then assess potential interactions and modify the treatment plan as needed to ensure the safest possible therapy for the individual cat.

Robenacoxib should not be administered concurrently with other NSAIDs or corticosteroids due to the significantly increased risk of gastrointestinal ulceration, bleeding, and kidney damage. This includes other prescription NSAIDs such as meloxicam, as well as over-the-counter human NSAIDs like aspirin, ibuprofen, or naproxen, which are extremely dangerous in cats even without concurrent robenacoxib use. Corticosteroids such as prednisolone or dexamethasone also increase gastrointestinal and renal risks when combined with NSAIDs. A washout period is typically required when transitioning between different NSAIDs or between NSAIDs and corticosteroids, with the specific duration depending on the drugs involved. Other drugs that may interact with robenacoxib include anticoagulants, diuretics, ACE inhibitors, and certain antibiotics, as well as drugs that are highly protein-bound or metabolized by similar hepatic pathways.

Dietary factors and supplements can also interact with robenacoxib therapy. As mentioned in the dosing section, food affects the absorption of oral robenacoxib, with administration on an empty stomach resulting in optimal drug absorption. Fish oil supplements, while beneficial for joint health in some contexts, may enhance the antiplatelet effects of NSAIDs and should be used cautiously in cats receiving robenacoxib. Other supplements with anticoagulant or anti-inflammatory properties, such as certain herbal products, should be discussed with the veterinarian. Nutritional supplements containing compounds that affect kidney or liver function should also be evaluated for potential interactions.

Monitoring for drug interactions during robenacoxib therapy involves both clinical observation and, in some cases, laboratory testing. Cats receiving robenacoxib concurrently with other medications should be observed closely for any signs of adverse effects, including gastrointestinal upset, changes in urination, increased bleeding tendency, or unexpected behavioral changes. Veterinarians may recommend baseline and follow-up blood work to monitor kidney and liver function, particularly in cats receiving concurrent medications that may also affect these organs. Signs of potential drug interactions should be reported to the veterinarian promptly, including any new symptoms that develop after starting robenacoxib or changes in the cat's response to other medications they are receiving.

General precautions for robenacoxib use in cats begin with ensuring accurate body weight measurement and appropriate dosing. Cats should be weighed at each veterinary visit using a properly calibrated scale, as weight changes can occur and affect dosing requirements. The lowest effective dose for the shortest duration necessary to achieve pain control should be used to minimize the risk of adverse effects. Cat owners should follow veterinary instructions precisely regarding dose amount, timing, and duration of therapy, and should not adjust doses or extend treatment without veterinary authorization. Any concerns about the cat's response to medication should be discussed with the veterinarian rather than addressed through independent dosing changes.

Breed-specific considerations for robenacoxib are not as well-documented as for some other drug classes, but general awareness of breed sensitivities is appropriate. Some breeds may have genetic variations affecting drug metabolism that could influence response to robenacoxib or risk of adverse effects. Breeds with known predispositions to kidney disease, such as Persians and Abyssinians, may require particularly careful evaluation before NSAID therapy. Similarly, breeds with cardiac predispositions should be evaluated for underlying heart disease before starting robenacoxib. Veterinarians familiar with breed-specific health concerns can provide guidance on whether additional precautions or monitoring are warranted for individual cats based on their breed background.

Environmental precautions and safe handling of robenacoxib are important for protecting both the medication's integrity and household members. The medication should be stored securely out of reach of children and other pets to prevent accidental ingestion. People handling robenacoxib tablets should wash their hands after administration, and those with known NSAID sensitivities should take particular care to avoid direct contact with the medication. In multi-pet households, care should be taken to ensure only the prescribed cat receives robenacoxib, as dosing requirements differ between species and accidental administration to dogs or other animals could be problematic.

Monitoring cats during robenacoxib treatment involves observing for both therapeutic efficacy and potential adverse effects. Signs of effective pain control include improved mobility, increased activity, better appetite, and more normal behavior patterns. Conversely, signs of inadequate pain control such as continued reluctance to move, vocalization, hiding, or decreased interaction may indicate the need for veterinary reassessment. Monitoring for adverse effects includes watching for any gastrointestinal signs, changes in drinking or urination, lethargy, or behavioral changes. Owners should know which signs warrant immediate veterinary attention versus those that can be reported at a scheduled recheck.

Special populations of cats require additional precautions when considering robenacoxib therapy. Geriatric cats often have some degree of subclinical kidney or liver dysfunction that may not be apparent without blood work, making pre-treatment screening particularly important in this population. Senior cats may also be more susceptible to adverse effects and may benefit from reduced doses or shorter treatment durations. Kittens younger than four months should generally not receive robenacoxib due to immature organ function and lack of safety data. Immunocompromised cats or those with chronic diseases require careful individual assessment to determine whether the benefits of NSAID therapy outweigh the risks in their specific situation.

Robenacoxib should be stored according to the manufacturer's specifications to maintain medication stability and effectiveness. Oral tablets should be kept at controlled room temperature, typically between 68°F and 77°F (20°C to 25°C), in their original packaging until use. The medication should be protected from excessive heat, moisture, and direct light, which can degrade the active ingredient. Storage locations near heat sources such as stoves, heating vents, or sunny windowsills should be avoided. Bathroom medicine cabinets, despite their convenience, may expose medications to humidity and temperature fluctuations that can affect stability. A cool, dry location such as a bedroom closet or kitchen cabinet away from the stove and sink is typically appropriate for tablet storage.

The injectable formulation of robenacoxib requires specific storage conditions that may differ from the oral tablets. Veterinary hospitals typically maintain injectable robenacoxib under controlled conditions, and any injectable product dispensed for at-home use should include specific storage instructions from the veterinarian. Some injectable formulations may require refrigeration while others are stable at room temperature. The vial should be examined before each use for any changes in color, clarity, or the presence of particulate matter, and should not be used if abnormalities are observed. Expiration dates on both oral and injectable formulations should be checked regularly, and expired medications should not be administered to cats.

Safe handling and disposal of robenacoxib protects both household members and the environment. The medication should be stored securely out of reach of children and pets to prevent accidental ingestion. Used or expired robenacoxib should not be disposed of in household trash or flushed down toilets, as this can lead to environmental contamination. Many communities offer pharmaceutical take-back programs through pharmacies, veterinary clinics, or community collection events that provide appropriate disposal options. In the absence of take-back programs, the FDA provides guidance on proper home disposal of medications. Any unused medication remaining after the prescribed course is complete should be disposed of properly rather than saved for potential future use without veterinary authorization. Compounded formulations of robenacoxib may have different stability characteristics than commercial products and should be used within the timeframe specified by the compounding pharmacy.

Most cats tolerate robenacoxib well regardless of breed when the medication is used appropriately and patients are properly selected. However, understanding breed-specific health predispositions can help veterinarians and cat owners make informed decisions about pain management strategies. Some breeds have higher incidences of conditions that may affect robenacoxib safety, and awareness of these predispositions allows for appropriate precautions. Veterinarians consider breed background as part of the overall patient assessment, along with individual health history, current condition, and concurrent medications, to determine whether robenacoxib is the best choice for a particular cat.

Certain breeds have documented predispositions to kidney disease, which is particularly relevant for NSAID therapy including robenacoxib. Persian and Himalayan cats have increased rates of polycystic kidney disease, while Abyssinians may be prone to renal amyloidosis. Maine Coons, Siamese, and various other breeds have documented kidney disease predispositions. Cats of these breeds may require pre-treatment screening of kidney function before starting robenacoxib, and may need more frequent monitoring during therapy. Breeds with cardiac predispositions, such as Maine Coons, Ragdolls, and certain other breeds prone to hypertrophic cardiomyopathy, should have cardiac status evaluated before NSAID therapy, as heart disease may affect the safety of these medications.

Body size and conformation vary significantly among cat breeds, affecting dosing precision and formulation selection. Large breeds such as Maine Coons and Norwegian Forest Cats may require different tablet strengths than smaller breeds like Singapuras or Cornish Rex. The availability of multiple tablet strengths allows for appropriate dosing across the range of feline body sizes, but accurate weight measurement remains essential regardless of breed. Very small cats may benefit from compounded formulations that allow for more precise dose adjustment. Body condition also matters, as overweight cats should be dosed based on lean body weight rather than total weight to avoid potential overdosing.

Age-related considerations apply across all breeds but may manifest differently in breeds with varying life expectancies and age-related disease patterns. Kittens of any breed should generally not receive robenacoxib until at least four months of age due to immature liver and kidney function that affects drug metabolism and elimination. Geriatric cats of all breeds are more likely to have subclinical organ dysfunction that increases NSAID risk, though the age at which a cat is considered geriatric varies somewhat by breed, with larger breeds often aging faster than smaller breeds. Baseline blood work to assess kidney and liver function is particularly important in older cats of any breed before initiating robenacoxib therapy. Regular monitoring throughout treatment helps ensure ongoing safety in these potentially more vulnerable patients.

Within the NSAID class, meloxicam represents the other most commonly used option for feline pain management and serves as the primary alternative to robenacoxib. Meloxicam is a COX-2 preferential NSAID that has been available for feline use longer than robenacoxib and is familiar to most veterinary practitioners. While both drugs provide effective analgesia and anti-inflammatory effects, robenacoxib's higher COX-2 selectivity may offer theoretical safety advantages in some patients. Meloxicam is available in oral liquid formulation, which some owners find easier to administer than tablets, particularly for cats resistant to pilling. The choice between robenacoxib and meloxicam often depends on individual patient factors, veterinarian preference, and practical considerations such as formulation preference and cost.

When NSAID therapy is not appropriate or additional pain control is needed, veterinarians may turn to different drug classes for feline pain management. Opioid analgesics such as buprenorphine provide potent pain relief without the gastrointestinal and renal concerns associated with NSAIDs, making them appropriate for cats with kidney disease or other NSAID contraindications. Gabapentin has become widely used for pain management in cats, particularly for chronic pain conditions and as part of multimodal analgesia protocols. Frunevetmab, a monoclonal antibody targeting nerve growth factor, represents a newer option for managing osteoarthritis pain in cats without the organ concerns associated with NSAIDs. These alternative approaches offer options when NSAIDs are contraindicated or when combination therapy would provide better pain control.

Complementary therapies can support pharmaceutical pain management in cats and may allow for reduced medication doses or provide additional comfort. Joint supplements containing glucosamine, chondroitin, and omega-3 fatty acids may support joint health in cats with osteoarthritis. Environmental modifications such as providing soft bedding, low-entry litter boxes, and easy access to food and water can reduce pain from movement in cats with musculoskeletal conditions. Physical rehabilitation techniques, including controlled exercise, massage, and acupuncture, are increasingly available through veterinary specialists and may complement drug therapy. Weight management is crucial for overweight cats with joint pain. Any complementary therapies should be discussed with the veterinarian to ensure they are appropriate for the individual cat and do not interfere with prescribed medications. Substituting alternative treatments for prescribed robenacoxib without veterinary approval is not recommended, as this could result in inadequate pain control.